相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1996
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Hanmi Pharmaceutical has been selected as the final beneficiary of South Korea's "AX One-Stop Voucher Support Program" to integrate AI into quality assurance operations. - The two-year "Hanmi Q-Agent" project will train a proprietary language model on approximately 4,000 SOPs at the Pyeongtaek Bio Plant, with first-year costs of roughly 1.7 billion won. - The AI system will support quality assurance for "Epe," a Korea-customized obesity treatment slated for launch in the second half of the year. - The initiative aims to shift manual quality documentation to an AI-collaborative process, freeing employees for new drug development and global business operations.
- South Korea lowered the national health insurance reimbursement rate for generic drugs to 45 percent of the original drug's price, down from 53.55 percent, effective Aug. 1. - Industry groups estimate the overhaul could result in as much as 3.6 trillion won in lost sales and 14,800 fewer jobs across the pharmaceutical and biotech sector. - Korean drugmakers including Ildong Pharmaceutical and Chong Kun Dang have declared emergency management systems, consolidated sales organizations, and cut R&D budgets in response. - The government designed the cuts to reduce reliance on generics and encourage innovation, offering preferential rates of 60 percent and 50 percent to innovative and quasi-innovative companies.
- The global automated liquid handling technologies market is projected to grow from US$2.7 billion in 2024 to US$7.4 billion by 2034 at a CAGR of 10.6%. - Drug discovery and ADME-Tox research accounted for the largest application segment at 41.9% of market share in 2023, with pharmaceutical and biotechnology companies representing 52.3% of end users. - North America leads the market with 39.5% of global revenue, while Asia Pacific is expected to register the fastest growth driven by expanding R&D investments. - Integration of artificial intelligence, machine learning, and cloud-enabled laboratory automation is enhancing workflow optimization and data management capabilities across the sector.
- Samsung Bioepis presented subgroup analysis data from its global phase 3 trial of Obodence at the World Congress on Osteoporosis, demonstrating consistent therapeutic efficacy across diverse patient populations. - The analysis of 456 postmenopausal women with osteoporosis showed that demographic and disease-related factors did not affect treatment efficacy when comparing Obodence to its reference product Prolia. - Both drugs demonstrated consistent bone mineral density improvements at lumbar spine, total hip, and femoral neck after 12 months of treatment, reaffirming their biological similarity. - Obodence launched in Korea in July 2024 and is expanding globally through various market strategies, targeting Prolia's $4.41 billion global market.
- Eli Lilly is preparing to launch its oral anti-obesity drug Orforglipron in the U.S. next year, with plans for rapid introduction to the Korean market following FDA approval. - Novo Nordisk has applied for FDA approval of high-dose oral semaglutide 25mg and a 7.2mg high-dose Wegovy formulation, with decisions expected by early 2025. - Mounjaro has overtaken Wegovy as the leading obesity drug in Korea by monthly prescriptions, reaching 97,344 prescriptions in November 2024. - The WHO issued its first conditional recommendation for GLP-1-based anti-obesity drugs in December 2024, potentially leading to incorporation into public healthcare systems globally.
- Hanmi Pharmaceutical presented four posters at SITC demonstrating HM16390's novel IL-2 analog design that optimizes both alpha and beta receptor binding for improved therapeutic outcomes. - The drug selectively increases regulatory T cells in blood rather than tumors to reduce systemic toxicity while significantly boosting tumor-specific CD8+ T cells for enhanced antitumor efficacy. - Collaborative research with KAIST identified IL-2-related immune signaling pathways as predictive biomarkers for immunotherapy response across 5,000 patients and nine cancer types. - HM16390 is currently in global Phase 1 dose-escalation trials with plans to expand to combination studies with Keytruda in the first half of next year.
- Hanmi Pharmaceutical's HM97662, a next-generation dual EZH1/2 inhibitor, demonstrated manageable safety and initial antitumor activity in a Phase 1 clinical trial presented at ESMO 2025. - The study enrolled 28 patients with advanced solid tumors across seven dose groups (50-350mg), with one uterine sarcoma patient achieving partial response and one ovarian cancer patient maintaining stable disease for over 15 months. - The dual inhibition mechanism targeting both EZH1 and EZH2 proteins aims to overcome resistance limitations of existing EZH2-selective inhibitors by more effectively blocking cancer cell growth pathways.
- Hanmi Pharmaceutical will present six studies on its next-generation obesity drug candidates HM15275 and HM17321 at the American Diabetes Association 2025 annual meeting in Chicago. - HM15275, a triple agonist targeting GLP-1, GIP, and glucagon receptors, has demonstrated potential for more than 25% total body weight loss while minimizing lean mass loss in preclinical studies. - HM17321 represents the world's first UCN2-based obesity therapy designed to simultaneously reduce fat mass and increase muscle mass, offering a fundamentally different mechanism from current GLP-1 therapies. - Both drug candidates are positioned to initiate Phase 2 and Phase 1 clinical trials respectively in the second half of 2025, potentially addressing key limitations of existing obesity treatments.
- DelveInsight's analysis reveals 4+ key companies are developing 6+ therapies for congenital hyperinsulinism, with emerging treatments including CRN-04777, HM 15136, RZ358, and dasiglucagon expected to significantly impact the market. - Recent regulatory developments include FDA's Breakthrough Therapy Designation for RZ358 in January 2025 and removal of clinical holds in September 2024, while Zealand Pharma received a Complete Response Letter for dasiglucagon in October 2024. - The congenital hyperinsulinism market is anticipated to grow with significant CAGR during 2020-2034, driven by increasing disease awareness and research activities, though challenges remain with high treatment costs and diagnostic complexities.
- MSD (Merck & Co.) has secured non-exclusive global rights to Cyprumed's oral peptide delivery platform, potentially transforming injectable peptide treatments into convenient tablet formulations. - The agreement includes up to $493 million in milestone payments and grants MSD options for exclusive licensing of the technology for specific targets, with MSD leading all development and commercialization efforts. - Cyprumed's innovative tablet formulation technology offers superior bioavailability using approved pharmaceutical excipients, potentially advancing MSD's macrocyclic peptide portfolio including enlicitide decanoate and efinopegdutide.
